Goodwin advised Moderna, Inc. on the deal. Moderna, Inc. (Nasdaq:MRNA) announced its strategic collaboration with Generation Bio Co. (Nasdaq:GBIO) to combine Moderna’s biological and technical expertise with...
You must be a Standard 1 Year member to access this content.
Goodwin advised OncoC4 on the deal. OncoC4 announced its agreement with BioNTech SE pursuant to which BioNTech receives an exclusive worldwide license to co-develop and commercialize OncoC4’s...
You must be a Standard 1 Year member to access this content.
Morgan Lewis represented Merck in the transaction. Merck closed its exclusive license and collaboration agreement with Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd., to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Pixomondo on the deal. Pixomondo announced its acquisition by Sony Pictures Entertainment from Mayfair Equity Partners. The acquisition of Pixomondo, alongside Sony Pictures Imageworks...
You must be a Standard 1 Year member to access this content.
Goodwin Procter, McCarthy Tétrault and Skadden, Arps, Slate, Meagher & Flom advised Ritchie Bros. Incorporated, while Cooley and Blake, Cassels & Graydon advised IAA on the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised TA Associates on the deal. TA Associates announced its strategic growth investment in Veracode, taking a majority equity position in the business. Veracode is...
You must be a Standard 1 Year member to access this content.
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Cast & Crew in the transaction while Goodwin advised TA Associates and Backstage Holdings. Cast & Crew, a leading end-to-end cloud-based platform...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Novo on the deal. Novo announced the completion of its $90 million Series B Preferred Stock financing that values the startup at $700 million....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised SWORD Health on the deal. SWORD Health announced its Series D financing. This brings the total primary and secondary transactions to more than $320...
You must be a Standard 1 Year member to access this content.
